Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2025 14:30 ET | Source: Novartis Pharma AG

Novartis and US government reach agreement on lowering drug prices in the US

Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be made available through direct-to-patient platforms in 2026Company...
December 09, 2025 07:30 ET | Source: Novartis Pharma AG

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients treated with...
November 20, 2025 01:00 ET | Source: Novartis Pharma AG

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc1Peak sales guidance upgraded for...
November 12, 2025 17:00 ET | Source: Novartis Pharma AG

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate...
November 04, 2025 01:15 ET | Source: Novartis Pharma AG

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G)...
October 29, 2025 10:30 ET | Source: Novartis Pharma AG

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across secondary outcome measures, and...
October 28, 2025 09:52 ET | Source: Novartis Pharma AG

Novartis completes acquisition of Tourmaline Bio

Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of common...
October 28, 2025 02:00 ET | Source: Novartis Pharma AG

Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt

Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im dritten Quartal um +7% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich um +7% (kWk, +6% USD)Das Umsatzwachstum beruhte...
October 28, 2025 02:00 ET | Source: Novartis Pharma AG

Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance

Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +7% (cc1, +8% USD) and core operating income1 grew +7% (cc, +6% USD) Sales growth was driven by continued strong execution on priority...
October 26, 2025 13:00 ET | Source: Novartis Pharma AG

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseasesAdvances the Novartis...